Longeveron LLC
Yahoo Finance • 23 days ago
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease
Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s diseaseThis encouraging clinical trial data adds to the body of evidence supportin... Full story
Yahoo Finance • 29 days ago
Longeveron® to Present at the 37th Annual Roth Conference
MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announc... Full story
Yahoo Finance • last month
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to... Full story
Yahoo Finance • last month
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025
MIAMI, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announce... Full story
Yahoo Finance • last month
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
MIAMI, Feb. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 79th Emerging Growth Conference on February 18 & 19, 2025. The Emerging Growth Conference identifies... Full story
Yahoo Finance • last month
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™
Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of “laromestrocel” on the INN List issued by the World Health Organization (WHO)Lomecel-B™ is a proprietary, scalable, allogeneic cellular therapy bei... Full story
Yahoo Finance • 2 months ago
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025
MIAMI, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announce... Full story
Yahoo Finance • last year
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa’el Hashad, CEO of Longeveron Inc.
LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The... Full story
Yahoo Finance • last year
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
Top Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks Long-term Survival Data from ELPIS 1 Trial to be Present... Full story
Yahoo Finance • last year
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announce... Full story
Yahoo Finance • last year
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer’s
LOS ANGELES, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via IBN -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threate... Full story
Yahoo Finance • last year
Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as h... Full story
Yahoo Finance • last year
Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
MIAMI, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as h... Full story
Yahoo Finance • last year
Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer’s Disease
Company to Hold Conference Call & Webcast Today, October 5 at 8:00am ET Primary Endpoint of Safety Met Across all Study GroupsStatistical Significance Met for Secondary Endpoint Composite Alzheimer’s Disease Score (CADS) for Lomecel-B™ Lo... Full story
Yahoo Finance • 2 years ago
Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related condi... Full story
Yahoo Finance • 2 years ago
Presenting on the Emerging Growth Conference on September 6 and 7 Register Now
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023. The Emerging Growth Conference identifies... Full story
Yahoo Finance • 2 years ago
Longeveron to Participate in the 149th Annual National Investment Banking Association Conference
MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related condit... Full story
Yahoo Finance • 2 years ago
Longeveron Rights Offering Subscription Period Begins
MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related condit... Full story
Yahoo Finance • 2 years ago
Longeveron Rights Offering Declared Effective and Calendar Finalized
MIAMI, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as h... Full story
Yahoo Finance • 2 years ago
Longeveron to Host Key Opinion Leader Event on Medicinal Signaling Cells (MSCs) for Hypoplastic Left Heart Syndrome (HLHS) with Lomecel-B™ on August 16, 2023
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it will host a virtual... Full story
